Probiotics and paraprobiotics in viral infection: Clinical application and effects on the innate and acquired immune systems

Current Pharmaceutical Design

Volumn 24, Issue 6, 2018, Pages 710-717

  Kanauchi, Osamu ^a,b   Andoh, Akira ^a   Abubakar, Sazaly ^c   Yamamoto, Naoki ^d,e  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KIRIN HOLDINGS CO LTD   (Japan)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Interferon; Paraprobiotics; Plasmacytoid dendritic cell; Probiotics; Vaccines; Virus infection

Indexed keywords

INFLUENZA VACCINE; INTERFERON; PARAPROBIOTIC AGENT; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; BIFIDOBACTERIUM ANIMALIS; COMMON COLD; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; EPSTEIN BARR VIRUS INFECTION; HAND WASHING; HEPATITIS C; HUMAN; IMMUNOMODULATION; INFECTION PREVENTION; INFECTIOUS DIARRHEA; INFLUENZA; INFLUENZA VACCINATION; INNATE IMMUNITY; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOCOCCUS LACTIS; MUCOSAL IMMUNITY; NONHUMAN; NOROVIRUS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; QUARANTINE; REHYDRATION; REVIEW; RHINOVIRUS INFECTION; ROTAVIRUS; SACCHAROMYCES BOULARDII; VIRAL GASTROENTERITIS; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; ANIMAL; DRUG EFFECT; IMMUNOLOGY; MUCOSA; VIRUS;

ANIMALS; HUMANS; IMMUNITY, INNATE; MUCOUS MEMBRANE; PROBIOTICS; VIRUS DISEASES; VIRUSES;

EID: 85048856010     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612824666180116163411     Document Type: Review

References (74)

1. Alan H, Ian B, Nancy C, et al. Improving the selection and development of influenza vaccine viruses-Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015. Vaccine 2017; 35: 1104-9.
2. Liu S, Chan TC, Chu YT, et al. Comparative Epidemiology of Human Infections with Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome Coronaviruses among Healthcare Personnel. PLoS One 2016; 11: e0149988.
3. El Sayed SM, Abdelrahman AA, Ozbak HA, et al. Updates in diagnosis and management of Ebola hemorrhagic fever. J Res Med Sci 2016; 21: 84.
4. Sakkas H, Economou V, Papadopoulou C. Zika virus infection: Past and present of another emerging vector-borne disease. J Vector Borne Dis 2016; 53: 305-11.
5. Franchini M, Mannucci PM. Impact on human health of climate changes. Eur J Intern Med 2015; 26: 1-5.
6. Vasin AV, Temkina OA, Egorov VV, et al. Molecular mechanisms enhancing the proteome of influenza A viruses: an overview of recently discovered proteins. Virus Res 2014; 185: 53-63.
7. Taira M, Ogawa T, Nishijima H, et al. The first isolation of Zika virus from a Japanese patient who returned to Japan from Fiji in 2016. Jpn J Infect Dis 2017.
8. Nakayama E, Kotaki A, Tajima S, et al. Two different dengue virus strains in the Japanese epidemics of 2014. Virus Genes 2016; 52: 722-6.
9. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-7.
10. Jung A, Kato H, Kumagai Y, et al. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88. J Virol 2008; 82: 196-206.
11. Oviedo-Boyso J, Bravo-Patino A, Baizabal-Aguirre VM. Collaborative action of Toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria. Mediators Inflamm 2014; 2014: 432785.
12. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442: 39-44.
13. Lehtoranta L, Pitkaranta A, Korpela R. Probiotics in respiratory virus infections. Eur J Clin Microbiol Infect Dis 2014; 33: 1289-302.
14. Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol 2015; 21: 10644-53.
15. Memoli MJ, Morens DM, Taubenberger JK. Pandemic and seasonal influenza: therapeutic challenges. Drug Discov Today 2008; 13: 590-5.
16. Lindsay L, Wolter J, De Coster I, Van Damme P, Verstraeten T. A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review. BMC Infect Dis 2015; 15: 425.
17. Nagatake T, Ahmed K, Oishi K. Prevention of respiratory infections by povidone-iodine gargle. Dermatology 2002; 204 (Suppl 1): 32-6.
18. Heijne JC, Teunis P, Morroy G, et al. Enhanced hygiene measures and norovirus transmission during an outbreak. Emerg Infect Dis 2009; 15: 24-30.
19. Barik S. New treatments for influenza. BMC Med 2012; 10: 104.
20. Paules C, Subbarao K. Influenza. Lancet 2017.
21. Wu X, Wu X, Sun Q, et al. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics 2017; 7: 826-845.
22. Santosham M, Chandran A, Fitzwater S, et al. Progress and barriers for the control of diarrhoeal disease. Lancet 2010; 376: 63-7.
23. Bobo LD, Dubberke ER. Recognition and prevention of hospital-associated enteric infections in the intensive care unit. Crit Care Med 2010; 38: S324-34.
24. Dennehy PH. Effects of vaccine on rotavirus disease in the pediatric population. Curr Opin Pediatr 2012; 24: 76-84.
25. Perez-Lopez A, Behnsen J, Nuccio SP, Raffatellu M. Mucosal immunity to pathogenic intestinal bacteria. Nat Rev Immunol 2016; 16: 135-48.
26. Hall JA, Bouladoux N, Sun CM, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 2008; 29: 637-49.
27. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 2010; 107: 12204-9.
28. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008; 455: 808-12.
29. Goto Y, Uematsu S, Kiyono H. Epithelial glycosylation in gut homeostasis and inflammation. Nat Immunol 2016; 17: 1244-1251.
30. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011; 45 Suppl: S149-53.
31. Park MK, Ngo V, Kwon YM, et al. Lactobacillus plantarum DK119 as a probiotic confers protection against influenza virus by modulating innate immunity. PLoS One 2013; 8: e75368.
32. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-14.
33. Taverniti V, Guglielmetti S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr 2011; 6: 261-74.
34. Pimentel-Nunes P, Soares JB, Roncon-Albuquerque R, Jr., Dinis-Ribeiro M, Leite-Moreira AF. Toll-like receptors as therapeutic targets in gastrointestinal diseases. Expert Opin Ther Targets 2010; 14: 347-68.
35. Gleeson M, Bishop NC, Struszczak L. Effects of Lactobacillus casei Shirota ingestion on common cold infection and herpes virus antibodies in endurance athletes: a placebo-controlled, randomized trial. Eur J Appl Physiol 2016; 116: 1555-63.
36. Nagata S, Asahara T, Ohta T, et al. Effect of the continuous intake of probiotic-fermented milk containing Lactobacillus casei strain Shirota on fever in a mass outbreak of norovirus gastroenteritis and the faecal microflora in a health service facility for the aged. Br J Nutr 2011; 106: 549-56.
37. Van Puyenbroeck K, Hens N, Coenen S, et al. Efficacy of daily intake of Lactobacillus casei Shirota on respiratory symptoms and influenza vaccination immune response: a randomized, double-blind, placebo-controlled trial in healthy elderly nursing home residents. Am J Clin Nutr 2012; 95: 1165-71.
38. Kumpu M, Kekkonen RA, Korpela R, et al. Effect of live and inactivated Lactobacillus rhamnosus GG on experimentally induced rhinovirus colds: randomised, double blind, placebo-controlled pilot trial. Benef Microbes 2015; 6: 631-9.
39. Sindhu KN, Sowmyanarayanan TV, Paul A, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2014; 58: 1107-15.
40. Makino S, Ikegami S, Kume A, et al. Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. Br J Nutr 2010; 104: 998-1006.
41. Nagai T, Makino S, Ikegami S, Itoh H, Yamada H. Effects of oral administration of yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 and its exopolysaccharides against influenza virus infection in mice. Int Immunopharmacol 2011; 11: 2246-50.
42. Makino S, Sato A, Goto A, et al. Enhanced natural killer cell activation by exopolysaccharides derived from yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. J Dairy Sci 2016; 99: 915-23.
43. Jespersen L, Tarnow I, Eskesen D, et al. Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. Am J Clin Nutr 2015; 101: 1188-96.
44. Rizzardini G, Eskesen D, Calder PC, et al. Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12(R) and Lactobacillus paracasei ssp. paracasei, L. casei 431(R) in an influenza vaccination model: a randomised, double-blind, placebo-controlled study. Br J Nutr 2012; 107: 876-84.
45. Maruyama M, Abe R, Shimono T, et al. The effects of non-viable Lactobacillus on immune function in the elderly: a randomised, double-blind, placebo-controlled study. Int J Food Sci Nutr 2016; 67: 67-73.
46. Pedone CA, Arnaud CC, Postaire ER, Bouley CF, Reinert P. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract 2000; 54: 568-71.
47. Merenstein D, Murphy M, Fokar A, et al. Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. Eur J Clin Nutr 2010; 64: 669-77.
48. Arimori Y, Nakamura R, Hirose Y, et al. Daily intake of heat-killed Lactobacillus plantarum L-137 enhances type I interferon production in healthy humans and pigs. Immunopharmacol Immunotoxicol 2012; 34: 937-43.
49. Hirose Y, Murosaki S, Yamamoto Y, Yoshikai Y, Tsuru T. Daily intake of heat-killed Lactobacillus plantarum L-137 augments acquired immunity in healthy adults. J Nutr 2006; 136: 3069-73.
50. Hirose Y, Yamamoto Y, Yoshikai Y, Murosaki S. Oral intake of heat-killed Lactobacillus plantarum L-137 decreases the incidence of upper respiratory tract infection in healthy subjects with high levels of psychological stress. J Nutr Sci 2013; 2: e39.
51. Oo KM, Lwin AA, Kyaw YY, et al. Safety and long-term effect of the probiotic FK-23 in patients with hepatitis C virus infection. Biosci Microbiota Food Health 2016; 35: 123-8.
52. Grandy G, Medina M, Soria R, Teran CG, Araya M. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infect Dis 2010; 10: 253.
53. Holscher HD, Czerkies LA, Cekola P, et al. Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial. JPEN J Parenter Enteral Nutr 2012; 36: 106S-17S.
54. Erdogan O, Tanyeri B, Torun E, et al. The comparition of the efficacy of two different probiotics in rotavirus gastroenteritis in children. J Trop Med 2012; 2012: 787240.
55. Sugimura T, Jounai K, Ohshio K, et al. Immunomodulatory effect of Lactococcus lactis JCM5805 on human plasmacytoid dendritic cells. Clin Immunol 2013; 149s509-18.
56. Sugimura T, Takahashi H, Jounai K, et al. Effects of oral intake of plasmacytoid dendritic cells-stimulative lactic acid bacterial strain on pathogenesis of influenza-like illness and immunological response to influenza virus. Br J Nutr 2015; 114: 727-33.
57. Shibata T, Kanayama M, Haida M, et al. Lactococcus lactis JCM5805 activates anti-viral immunity and reduces symptoms of common cold and influenza in healthy adults in a randomized controlled trial. J Funct Foods 2016; 24: 492-500.
58. Suzuki H, Kanayama M, Fujii T, Fujiwara D, Sugimura H. Effects of the beverage containing Lactococcus lactis subsp. lactis JCM5805 on anti-viral immune responses and maintenance of physical conditions Jpn Pharmacol Ther 2015; 43: 106-11-.
59. Sakata K, Sasaki Y, Jounai K, Fujii T, Fujiwara D. Preventive Effect of Lactococcus lactis subsp. lactis JCM 5805 Yogurt Intake on Influenza Infection among Schoolchildren. Health 2017; 9: 756-762.
60. Fujii T, Jounai K, Horie A, et al. Effects of heat-killed Lactococcus lactis subsp. lactis JCM 5805 on mucosal and systemic immune parameters, and antiviral reactions to influenza virus in healthy adults; a randomized controlled double-blind study. J Functional Foods 2017; 35: 513-21.
61. Chow KV, Sutherland RM, Zhan Y, Lew AM. Heterogeneity, functional specialization and differentiation of monocyte-derived dendritic cells. Immunol Cell Biol 2017; 95: 244-51.
62. Asselin-Paturel C, Boonstra A, Dalod M, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001; 2: 1144-50.
63. Hoene V, Peiser M, Wanner R. Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19. J Leukoc Biol 2006; 80: 1328-36.
64. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-50.
65. Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 2015; 15: 471-85.
66. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006; 344: 119-30.
67. Jounai K, Ikado K, Sugimura T, et al. Spherical lactic acid bacteria activate plasmacytoid dendritic cells immunomodulatory function via TLR9-dependent crosstalk with myeloid dendritic cells. PLoS One 2012; 7: e32588.
68. Jounai K, Sugimura T, Ohshio K, Fujiwara D. Oral administration of Lactococcus lactis subsp. lactis JCM5805 enhances lung immune response resulting in protection from murine parainfluenza virus infection. PLoS One 2015; 10: e0119055.
69. Trinchieri G, Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978; 147: 1314-33.
70. Guo Z, Tilburgs T, Wong B, Strominger JL. Dysfunction of dendritic cells in aged C57BL/6 mice leads to failure of natural killer cell activation and of tumor eradication. Proc Natl Acad Sci U S A 2014; 111: 14199-204.
71. Suzuki H, Ohshio K, Fujiwara D. Lactococcus lactis subsp. lactis JCM 5805 activates natural killer cells via dendritic cells. Biosci Biotechnol Biochem 2016; 80: 798-800.
72. Lee CK, Rao DT, Gertner R, et al. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000; 165: 3571-7.
73. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005; 174: 727-34.
74. Salminen S, Nybom S, Meriluoto J, et al. Interaction of probiotics and pathogens--benefits to human health? Curr Opin Biotechnol 2010; 21: 157-67.